Artivion VP regulatory Andrew Green sells $228,540 in stock

Published 04/12/2024, 22:16
Artivion VP regulatory Andrew Green sells $228,540 in stock

Andrew M. Green, Vice President of Regulatory at Artivion, Inc. (NYSE:AORT), has sold 7,618 shares of the company's common stock, according to a recent SEC filing. The shares were sold at a price of $30 each, amounting to a total transaction value of $228,540. The transaction comes as Artivion's stock trades near its 52-week high, having delivered an impressive 66% return year-to-date. Following this sale, Green retains ownership of 33,503 shares in the company. This transaction was carried out under a 10b5-1 trading plan that Green adopted on August 13, 2024. With analysts setting price targets between $32 and $35, and the stock currently appearing overvalued according to InvestingPro Fair Value metrics, investors seeking deeper insights can access comprehensive analysis and 12 additional ProTips through the InvestingPro platform.

In other recent news, medical device sector leader, Artivion, has reported strong financial performance in its Q3 2024 earnings call. The company revealed a 10% year-over-year increase in constant currency, with revenues reaching $95.8 million and adjusted EBITDA experiencing a significant 28% rise to $17.7 million. This growth was largely driven by robust sales of key products and market expansion in Latin America and Asia Pacific.

Artivion's product growth was notable with On-X, BioGlue, and stent grafts up by 15%, 14%, and 13% respectively. Despite a modest 2% growth in tissue processing, the company anticipates full-year revenue growth of 10% to 12%. The company's outlook also projects a net leverage decrease to 3.5x by year-end, with R&D expenses expected to remain consistent relative to sales.

Analysts have noted the company's U.S. market share increase by 55% and the potential $150 million market opportunity with the FDA approval of the AMDS device. The company is also focusing on the significant opportunity of BioGlue in China, expecting meaningful progress in H2 2025. These recent developments underline Artivion's continued growth and market expansion strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.